| Terminated | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type NCT06736509 | Axsome Therapeutics, Inc. | Phase 3 |
| Not Yet Recruiting | Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients NCT06620393 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 2 / Phase 3 |
| Withdrawn | Dronabinol for Agitation in Dementia Crossover Trial NCT05612711 | Ralph H. Johnson VA Medical Center | Phase 2 |
| Completed | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Di NCT06041646 | BioXcel Therapeutics Inc | Phase 4 |
| Recruiting | A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use NCT05783505 | Radboud University Medical Center | N/A |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III NCT05658510 | BioXcel Therapeutics Inc | Phase 3 |
| Terminated | A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia. NCT06217146 | M. H MediCane Ltd. | N/A |
| Recruiting | Clinical Trial on Agitation in Alzheimer's Dementia NCT05543681 | IGC Pharma, LLC | Phase 2 |
| Unknown | Physical Restraints in Intensive Care Unit Patients NCT04957238 | University Hospital, Clermont-Ferrand | N/A |
| Recruiting | Safe Brain Initiative, Operationalizing Precision Anaesthesia NCT05765162 | University of Southern Denmark | — |
| Completed | CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility T NCT05272501 | University College Copenhagen | N/A |
| Completed | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation NCT04947553 | Axsome Therapeutics, Inc. | Phase 3 |
| Recruiting | Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) NCT03926520 | Brent Forester | N/A |
| Active Not Recruiting | Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment o NCT04075435 | Mclean Hospital | EARLY_Phase 1 |
| Completed | Assessing Clinical Outcomes in Alzheimer's Disease Agitation NCT04797715 | Axsome Therapeutics, Inc. | Phase 3 |
| Completed | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder NCT04276883 | BioXcel Therapeutics Inc | Phase 3 |
| Completed | Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia NCT04251910 | BioXcel Therapeutics Inc | Phase 1 / Phase 2 |
| Unknown | Delirium, Agitation/Sedation, Pain and Dyspnea in Respiratory Intensive Care Unit (NIVILIUM) NCT03880084 | University of Modena and Reggio Emilia | — |
| Completed | Mindful Melody: Feasibility of Implementing Music Listening on an Inpatient Psychiatric Unit and Its Relation NCT04514432 | State University of New York - Upstate Medical University | — |
| Completed | Agitation Follow up After Introduction of a New Patient Care Algorithm NCT04053426 | University Hospital, Grenoble | — |
| Terminated | Olanzapine Versus Midazolam for Agitation NCT03899506 | Hennepin Healthcare Research Institute | — |
| Terminated | Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation NCT03110900 | University of Arkansas | Phase 4 |
| Completed | Addressing Dementia Via Agitation-Centered Evaluation NCT03226522 | Axsome Therapeutics, Inc. | Phase 2 / Phase 3 |
| Completed | Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation NCT03211897 | Hennepin Healthcare Research Institute | — |
| Completed | The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation NCT03208452 | Seoul National University Bundang Hospital | Phase 4 |
| Completed | Outcomes of Antipsychotic Medication Used in the Emergency Department NCT02504450 | Wake Forest University Health Sciences | — |
| Suspended | Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I NCT03513549 | Alexza Pharmaceuticals, Inc. | — |